Clinical trials: Thoracic Tumor
Carcinoma, Non-Small-Cell Lung
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC…
- Trial name
- LEPIDOPTERA (NCT07230691)
- Where
- 90 sites in Austria, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer, Lung Cancer
Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients
The aim of this placebo-controlled randomized study is to evaluate the effects of Melatonin 1mg/Zn 30% VNR/Mg 100% VNR (food supplement) in the management on sleep quality and mood alteration in cancer patients
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT02883790
- Testing
- Somnage
- Where
- 5 sites in Italy
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Lung Cancer
NovellusDx Cancer Early Detection Blood Test- Clinical Trial
NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature…
- Trial name
- NCT01883388
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fore Biotherapeutics
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
- Trial name
- NCT04025879
- Testing
- Nivolumab, Carboplatin, Cisplatin
- Where
- 108 sites in United States, Argentina and 20 more
- Volunteers
- 461 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasms
Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection
Study to assess the toxicity, pharmacokinetics, biodistribution and imaging characteristics associated with increasing doses of 131I-BIBH 1, to compare the uptake of 131I-BIBH 1 in tumour to that of normal tissue in patients with…
- Trial name
- NCT02199886
- Testing
- BIBH 1
- Volunteers
- 6 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02890069
- Testing
- PDR001, LCL161, Everolimus
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 298 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study…
- Trial name
- NCT04818983
- Where
- 95 sites in Japan
- Volunteers
- 470 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
The goal of this Phase 1 clinical trial is to learn whether KAN-001, an investigational live biotherapeutic product, can be safely given with pembrolizumab, with or without chemotherapy, to adults with PD-L1-positive, inoperable…
- Trial name
- NCT07910942
- Testing
- KAN-001, Pembrolizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Kanvas Biosciences
Non-small Cell Lung Cancer
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.
- Trial name
- ICOGEN (NCT01040780)
- Testing
- Icotinib, Gefitinib
- Where
- 27 sites in China
- Volunteers
- 399 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Non Small Cell Lung Cancer
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as…
- Trial name
- NCT06514027
- Testing
- BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- BeBetter Med Inc
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Lung Cancer
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
- Trial name
- NCT00047736
- Testing
- Tarceva (erlotinib HCl)
- Where
- 2 sites in United States
- Sponsor
- Genentech, Inc.
Lung Cancer, Non-Small Cell
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
- Trial name
- NCT01159964
- Testing
- Immunotherapeutic GSK2302032A, different formulations
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Solid Tumor, Non Small Cell Lung Cancer
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design.
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
- Trial name
- NCT03647163
- Testing
- VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vyriad, Inc.
Carcinoma, Non-Small-Cell Lung
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to…
- Trial name
- NCT00254904
- Testing
- Cisplatin, Gemcitabine, PF-3512676
- Where
- 120 sites in United States, Austria and 22 more
- Volunteers
- 839 people
- Sponsor
- Pfizer
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the…
- Trial name
- NCT07407933
- Testing
- YL201, Atezolizumab
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 118 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.